Novartis shares are trading lower following a patent ruling related to Entresto.
Portfolio Pulse from Benzinga Newsdesk
Novartis shares are trading lower following a patent ruling related to its drug, Entresto.
July 07, 2023 | 6:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novartis shares are expected to trade lower in the short term due to a patent ruling related to its drug, Entresto.
The patent ruling on Entresto, a drug produced by Novartis, is likely to have a negative impact on the company's stock price in the short term. This is because the ruling could potentially affect the company's exclusive rights to produce and sell the drug, which could in turn impact its revenues and profitability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100